OIG Cries Foul on CMS Sexual Dysfunction Drug Reimbursements
CMS said in a response that it agrees it should strengthen its internal controls, but said it did not concur that it should collaborate with the FDA to create and maintain a comprehensive list of such drugs or regularly disseminate that list to drug plans. "Part D sponsors are aware of the requirement that ED drugs are excluded and our existing prescription drug event edits eliminate the need for an additional drug list," said a response from CMS' administrator Don Berwick, MD.
But the OIG said in its response to CMS that "Nothing in CMS's comments has caused us to change our findings or recommendations. As the administrator of the Medicare Part D program, CMS has the primary responsibility to ensure that sponsors are administering their Part D plans appropriately."
It added that "the edits in place during the period of review were not entirely successful in preventing CMS from accepting prescription drug event data for the ED drugs listed in Appendix A."
Other erectile dysfunction brand drugs listed in an OIG appendix A as being paid for by Medicare under Part D other than Viagra, but whose costs were questioned include Cialis tablets, Caverject impulse and Caverject sterile powder sterile powder compounds for injection, Levitra tablets and Muse suppositories, although the total mounts for those drugs was much less, just over $54,000.
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CHS Hacked, 4.5M Patient Records Compromised
- CFO Exchange: Healthcare Leaders Share 5 Innovative Ideas
- Carondelet to Pay $35M to Settle Fraud Allegations